Join Mariusz Olejniczak, CEO of WDP Pharmaceuticals, and Diana Dupont-Roettger, Chief Scientific Alliance Officer of IAG, during a live webinar to discuss how advanced imaging can show early treatment effects in brain cancer.

Bringing a novel glioblastoma multiforme (‘GBM’) therapy to the market requires a robust clinical trial that will assess the effectiveness of the potential treatment. The design and delivery of such trials is a challenge.

If you are interested in a replay, please reach out to imaging.experts@ia-grp.com

Watch the webinar here

About the Webinar:

WPD Pharmaceuticals (‘WPD’) is a biotechnology research and development company focused on developing drug candidates involved in targeted therapy for brain cancers. Its lead drug candidate, Berubicin, is proposed for the treatment of GBM, an aggressive and incurable form of brain cancer. www.wpdpharmaceuticals.com

About Image Analysis Group (IAG)

IAG, Image Analysis Group is a unique partner to life sciences companies. IAG leverages expertise in medical imaging and the power of Dynamika™ – our proprietary cloud-based platform, to de-risk clinical development and deliver lifesaving therapies into the hands of patients much sooner.  IAG provides early drug efficacy assessments, smart patient recruitment and predictive analysis of advanced treatment manifestations, thus lowering investment risk and accelerating study outcomes. IAG bio-partnering takes a broader view on asset development bringing R&D solutions, operational breadth, radiological expertise via risk-sharing financing and partnering models.

Learn more:  wp1.ia-grp.com

Reach out: imaging.experts@ia-grp.com

Follow the Company: Linkedin

At IAG, we stand for recognition and empowerment of our female leaders. We invite you to join a live discussion with 4 inspirational female leaders of IAG. They will share their journey, career path and aspirations.

Watch this webinar

Dr. Olga Kubassova, IAG’s CEO and Founding Scientist, Dr. Diana Dupont-Roettger, IAG’s Chief Scientific Alliance Officer, Julia O’Lynn, IAG’s Imaging Specialist and Technologist, and Romiesa Hagoug, IAG’s Sn Project Manager.

IReach out:  imaging.experts@ia-grp.com

Key Discussion Points:

• My personal journey and joining clinical research industry,
• What does technology, science and entrepreneurship mean to me,
• My challenges and wins in day-to-day professional life,
• My aspirations, ambitions, and advice I want to give to the future leaders.

Followed by a discussion and Q&A.

Who Should Attend:

A person of any age, any gender, any occupation who feels that they can draw insights from our life stories and our journey and make these useful to your family, colleagues or friends.

If you cannot attend, just register and you will receive a replay link!

About Image Analysis Group (IAG)

IAG, Image Analysis Group is a unique partner to life sciences companies. IAG leverages expertise in medical imaging and the power of Dynamika™ – our proprietary cloud-based platform, to de-risk clinical development and deliver lifesaving therapies into the hands of patients much sooner.  IAG provides early drug efficacy assessments, smart patient recruitment and predictive analysis of advanced treatment manifestations, thus lowering investment risk and accelerating study outcomes. IAG bio-partnering takes a broader view on asset development bringing R&D solutions, operational breadth, radiological expertise via risk-sharing financing and partnering models.

Learn more:  wp1.ia-grp.com

Reach out: imaging.experts@ia-grp.com

Follow the Company: Linkedin

Join Dr. Olga Kubassova, Prof. Mikael Boesen, and Prof. Philip Mease during a live webinar to discuss how medical imaging can support targeted patient selection and more precise, objective assessment of the treatment impact.

Watch this webinar

About the Webinar:

One of the challenges in treatment of patients with Psoriatic Arthritis  (PsA) is the disease’s variable presentation. PsA may present in several clinical domains, including synovitis, dactylitis, skin disease, nail disease, spine disease (spondylitis) and each of these domains has subtly different immunologic pathophysiology drivers. Thus, drug developers may find that their new therapies do very well in individual patients or within some of the domains. Medical Imaging, quantitative biomarkers coupled with efficiencies of modern scanners can support targeted patient selection and more precise objective assessment of the treatment impact.

Key discussion points:

• How can we assess a new treatment efficacy through a clinical trial designed to give us a new comprehensive understanding of the treatment’s impact?
• Are there biomarkers and imaging techniques which can help differentiate patients early?
• State-of-the-art and emerging imaging techniques in trials of psoriatic arthritis
• Imaging biomarkers – in patient selection and efficacy assessment of new treatments targeting PsA

About Dr. Olga Kubassova:
Mathematician and computer scientist with 10+ years expertise in actively managing innovation in life science companies. Scientific interests are in quantitative imaging, development of novel efficacy methodologies, AI, Machine Learning in clinical trials.

About Prof. Mikael Boesen:
Mikael Boesen is currently employed as professor of radiology with focus on musculoskeletal imaging, and head of the musculoskeletal imaging and research at Copenhagen University and Bispebjerg and Frederiksberg Hospital in the Capital region of Denmark. He has 20 years hands-on international experience in clinical research in inflammatory and degenerative joint diseases and serves as a global PI and speaker as well as author of 120+ articles, 6 book chapters and 160 abstracts and he has served as supervisor of more than 20 PhD students and postdocs. He also brings together cross-therapeutic area expertise into MSK imaging from previous work in immuno-oncology and cardiac imaging and he currently spearheads implementation of artificial intelligence into radiological image analysis in Denmark, EU the US all of which he uses to helps drug developers and biotech companies to think outside the box when it comes to designing clinical trials and selecting appropriate imaging strategy within many therapeutic areas

About Prof. Philip Mease:
Dr. Mease is an international key opinion leader, researcher, educator and clinician who cares for patients at Seattle Rheumatology Associates, directs the rheumatology research division at Swedish Medical Center/Providence St. Joseph Health and is Clinical Professor of Medicine at the University of Washington in Seattle. His research interests include psoriatic arthritis and spondyloarthritis, rheumatoid arthritis, osteoarthritis, fibromyalgia and osteoporosis. He is a reviewer for multiple journals including New England Journal of Medicine, Lancet, Arthritis & Rheumatology, Arthritis Care & Research, Annals of the Rheumatic Diseases, The Journal of Rheumatology, and Seminars in Arthritis and Rheumatism. He is a past president and founding organizer of the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA), active contributor to Outcome Measures in Rheumatology Clinical Trials (OMERACT) research group and serves in an educational and advisory role for the FDA.

About Image Analysis Group (IAG)

IAG, Image Analysis Group is a unique partner to life sciences companies. IAG leverages expertise in medical imaging and the power of Dynamika™ – our proprietary cloud-based platform, to de-risk clinical development and deliver lifesaving therapies into the hands of patients much sooner.  IAG provides early drug efficacy assessments, smart patient recruitment and predictive analysis of advanced treatment manifestations, thus lowering investment risk and accelerating study outcomes. IAG bio-partnering takes a broader view on asset development bringing R&D solutions, operational breadth, radiological expertise via risk-sharing financing and partnering models.

Learn more:  wp1.ia-grp.com

Reach out: imaging.experts@ia-grp.com

Follow the Company: Linkedin

Join Dr. Olga Kubassova, CEO and Prof. Mikael Boesen, Head of Musculoskeletal Imaging Research during a live webinar to discuss optimal use of imaging to empower clinical development of novel therapeutics in osteoarthritis and cartilage repair.

Watch this webinar

About the Webinar:

A rising need for effective treatment that can both reduce pain and positively impact cartilage repair makes drug developers innovate in trial designs and use more informative biomarkers, including imaging.

Key discussion points:

• Patient selection and appropriate use of imaging to account for comorbidities
• FDA approved imaging endpoints for disease modification claims and use of AI in increasing their sensitivity
• Novel imaging and scoring for osteoarthritis and cartilage repair clinical trials

About Dr. Olga Kubassova:
Mathematician and computer scientist with 10+ years expertise in actively managing innovation in life science companies. Scientific interests are in quantitative imaging, development of novel efficacy methodologies, AI, Machine Learning in clinical trials.

About Prof. Mikael Boesen:
Prof. of musculoskeletal imaging, hands-on radiologist with 20 years of international experience in clinical research in inflammatory and degenerative joint diseases. Dr. Boesen is a global PI, speakers and author of 80+ articles and book chapters. He brings together cross-therapeutic area expertise and helps drug developers to think outside the box when it comes to designing clinical trials and selection imaging strategy.

About Image Analysis Group (IAG)

IAG, Image Analysis Group is a unique partner to life sciences companies. IAG leverages expertise in medical imaging and the power of Dynamika™ – our proprietary cloud-based platform, to de-risk clinical development and deliver lifesaving therapies into the hands of patients much sooner.  IAG provides early drug efficacy assessments, smart patient recruitment and predictive analysis of advanced treatment manifestations, thus lowering investment risk and accelerating study outcomes. IAG bio-partnering takes a broader view on asset development bringing R&D solutions, operational breadth, radiological expertise via risk-sharing financing and partnering models.

Learn more:  wp1.ia-grp.com

Reach out: imaging.experts@ia-grp.com

Follow the Company: Linkedin

Join our expert team to discuss the role of new technologies and imaging that support successful oncology clinical trial delivery.

Watch this webinar

Request password: imaging.experts@ia-grp.com

About the Webinar:

IAG’s imaging experts will share their experience in designing and delivering oncology clinical trials, that use quantitative imaging alongside standard radiographic response criteria, such as RECIST 1.1, iRECIST, RANO, Lugano.

The individual steps that are crucial for successful imaging data management that complies with latest regulatory requests will be outlined and discussed.

In addition, the team will highlight how the use of DYNAMIKA, IAG’s cloud based trial infrastructure, adds efficiencies and cost savings.

Key discussion points:

• Quality, Integrity and Security of data in a cloud-based trial infrastructure
• Speed of the processes and ability to make decisions fast
• Change between high level trial overview and details
• Real time availability of data
• Transparency of stakeholders’ performance
• Integration of Advanced Imaging

About Image Analysis Group (IAG)

IAG, Image Analysis Group is a unique partner to life sciences companies. IAG leverages expertise in medical imaging and the power of Dynamika™ – our proprietary cloud-based platform, to de-risk clinical development and deliver lifesaving therapies into the hands of patients much sooner.  IAG provides early drug efficacy assessments, smart patient recruitment and predictive analysis of advanced treatment manifestations, thus lowering investment risk and accelerating study outcomes. IAG bio-partnering takes a broader view on asset development bringing R&D solutions, operational breadth, radiological expertise via risk-sharing financing and partnering models.

Learn more:  wp1.ia-grp.com

Reach out: imaging.experts@ia-grp.com

Follow the Company: Linkedin

Re-thinking why trials fail and how to balance an optimal trial design with FDA prospective, Dr. Lee Simon is talking about a holistic approach to trial design and regulatory approval to maximize the changes of access while accelerating drug development.

Join our live webinar – “Optimizing Development Programs for Regulatory Approvals: The Importance of Phase II” – presented by Dr. Lee Simon, IAG’s Member of Scientific Advisory board and world-class scientist, with vast experience in taking new drugs through all stages of the development.

Key discussions points:

• Limitations of RCTs and why they fail?
• Regulatory pathways in the EU and USA
• Innovation in trial design vs FDA perspective

About the Webinar:

This webinar is organized by IAG, Image Analysis Group, a strategic partner to bio-pharmaceutical companies developing new treatments to improve patients’ lives. IAG broadly leverages its core imaging expertise, proprietary technology platform DYNAMIKA and capabilities to support an objective early go no/ go decision and drive excellence for tomorrow’s innovative therapeutic agents with speed. We fuse decades of therapeutic insights, risk-sharing business model and agile culture to accelerate novel drug development. wp1.ia-grp.com

Dr. Lee Simon is a rheumatologist, physician and research scientist with extensive drug development experience. He served as a director of FDA division for of Analgesic, Anti-inflammatory and Ophthalmologic Drug Products and currently advises many biotech and pharma companies on designing impactful clinical programs.

Questions? Please email imaging.experts@ia-grp.com

Data is your evidence of drug efficacy. It is the ‘must have’ of your clinical development program.

Imaging data is a rich source of information of objective response and early evidence of efficacy.  It reveals different dimensions of your drug’s MoA.

…and you can literally SEE your patients’ response.

The power of imaging-based evidence is hidden under a pile of inefficiencies associated with its collection and the screaming absence of quantitative approaches to explain its value.

Watch this webinar to discuss how to streamline imaging clinical trials and accelerate drug efficacy decisions.

PART 1: MODERN TRIAL INFRASTRUCTURE: STREAMLINING TRIAL OPERATIONS

password: IAG2020

Key Discussion Points:

• DYNAMIKA in a global multi-centre trial setting
• AI-powered controls over your data quality
• Insight into the advanced data analytics

PART 2: DYNAMIKA & QUANTITATIVE IMAGE ANALYSIS LIBRARIES

password: IAG2020

Key Discussion Points:

• Advanced quantitative approaches
• Radiomics, AI and Machine Learning for assessment of treatment response
• Making efficacy decisions in clinical trials

The webinars will presented by IAG’s leadership team and project managers and scientists.

At IAG, we developed DYNAMIKA to help bio-pharma innovators turning the page and steping into the new era of efficiencies and objective evidence.

IAG has been driving the use of quantitative imaging as an early evidence for drug development for over a decade.

DYNAMIKA is our platform that brings together smart image analysis methodologies, AI and Machine Learning to ensure speed and cost-effectiveness, while delivering true insights about your mechanism of action and patients’ response, in real-time.

About the Speakers:

Dr. Olga Kubassova, CEO of IAG, Image Analysis Group. She is a mathematician, computer scientist and entrepreneur, playing a significant role in the development and use of medical imaging in clinical research and diagnosis. 

Dr. Jamshid Dehmeshki, CTO of IAG, has over 20 years of experience in medical image analysis particularly in developing computer aided diagnosis systems. He is AI expert who tool products from conception to FDA approval. 

Questions or need help registering, please email <imaging.experts@ia-grp.com> 

Non-invasive methods are needed to enhance our understanding of complex neuro–pathologies. Novel imaging strategies can advance neurology and neuro–oncology clinical trials by providing deep analysis of disease progression and treatment response.

Watch this webinar

“Novel Imaging Approaches for Precision Medicine in Neuro-Oncology” .

Key discussions points:

• Current challenges and unmet needs for neuro-oncology imaging
• Novel neuro-imaging strategies in clinical trials
• A novel paradigm in decision-making: Radiological Phenotyping, True Progression vs. Pseudo-Progression

This webinar is organized by IAG, Image Analysis Group, a strategic partner to bio-pharmaceutical companies developing new treatments to improve patients’ lives. IAG broadly leverages its core imaging expertise, proprietary technology platform DYNAMIKA and capabilities to support an objective early go no/ go decision and drive excellence for tomorrow’s innovative therapeutic agents with speed. We fuse decades of therapeutic insights, risk-sharing business model and agile culture to accelerate novel drug development. wp1.ia-grp.com

Prof. Sotirios Bisdas is a consultant neuroradiologist and MRI Lead in the Department of Neuroradiology at the National Hospital for Neurology in London, Senior Lecturer in Neuroradiology at the Institute of Neurology University College London, and Professor of Radiology at Eberhard Karls University in Tübingen, Germany. He has authored over 130 peer-reviewed publications and serves as member of the editorial board of several leading journals in Radiology and Neuroradiology. He is also reviewer for leading journals in Neuroimaging, member of the Executive Committee of the European Society of Head and Neck Radiology, and member of the Head and Neck committee of the European Society of Neuroradiology.

Questions? Email to: <imaging.experts@ia-grp.com>

Traditional trial designs and endpoints are no longer suited for the fast-changing clinical Immuno-Oncology (IO) development. The methodologies and design of cancer clinical trials are under profound changes: umbrella, basket, or platform designs, all create a unique opportunity to drive collaboration, coordination, and accelerated innovation. Non-invasive imaging biomarkers can have a unique contribution by helping to understand the underlying biology behind various cancers. Amongst other biomarkers, they create the hope of a more focused and personalized medicine, which has the potential to bring more efficient and tailored treatments to patients.

Watch this webinar

Key discussion points:

• Understanding Pseudo-Progression through quantification of changes in the tumour microenvironment
• Machine Learning for non-invasive Imaging Phenotyping
• Machine Learning in Digital Pathology
• Predicting immunotherapy response through advanced imaging marker
• IAG’s proprietary cloud technology that supports umbrella, basket, or platform designs to create a unique opportunity to drive collaboration, coordination, and accelerated innovation in the IO field

About Image Analysis Group (IAG)

IAG, Image Analysis Group is a unique partner to life sciences companies. IAG leverages expertise in medical imaging and the power of Dynamika™ – our proprietary cloud-based platform, to de-risk clinical development and deliver lifesaving therapies into the hands of patients much sooner.  IAG provides early drug efficacy assessments, smart patient recruitment and predictive analysis of advanced treatment manifestations, thus lowering investment risk and accelerating study outcomes. IAG bio-partnering takes a broader view on asset development bringing R&D solutions, operational breadth, radiological expertise via risk-sharing financing and partnering models.

Learn more:  wp1.ia-grp.com

Reach out: imaging.experts@ia-grp.com

Follow the Company: Linkedin